Kolexia
Laguerre Brigitte
Oncologie médicale
Centre Eugène Marquis
Rennes, France
257 Activités
0 Followers

Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Carcinomes Néphrocarcinome Tumeurs de la prostate Tumeurs du rein Métastase tumorale Tumeurs prostatiques résistantes à la castration Récidive tumorale locale Tumeurs de la vessie urinaire Adénocarcinome

Industries

Ipsen
18 collaboration(s)
Dernière en 2023
Janssen
16 collaboration(s)
Dernière en 2023
Bayer
15 collaboration(s)
Dernière en 2023
Astellas
5 collaboration(s)
Dernière en 2023

Dernières activités

STARTER: A National, Multicenter, Phase III Randomized Controlled Trial to Assess the Impact of a One-year Supervised Physical Activity Program to Reduce Long-term Cancer-related Fatigue in Metastatic Testicular Germ Cell Tumor Patients
Essai Clinique (Centre Léon-Bérard)   20 février 2024
ANTICIPRO: Before and After Study, Evaluating the Efficiency of an Anticipated Personalization of the Management in Day Hospital Unit Based on a Collection of the PROs Via a Digital Tool
Essai Clinique (Centre Eugène Marquis)   06 février 2024
A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma (JAVELIN Bladder Medley): A Phase II, Multicenter, Randomized, Open Label, Parallel-Arm, Umbrella Study of Avelumab (MSB0010718C) in Combination With Other AntiTumor Agents as a Maintenance Treatment in Participants With Locally Advanced or Metastatic Urothelial Carcinoma Whose Disease Did Not Progress With First Line Platinum-Containing Chemotherapy (JAVELIN Bladder Medley)
Essai Clinique (Emd Serono)   05 février 2024
Safety and efficacy of nivolumab in elderly patients with metastatic clear cell renal cell carcinoma: Analysis of the NIVOREN GETUG-AFU 26 study.
European journal of cancer (Oxford, England : 1990)   03 février 2024
Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365): Phase Ib/II Trial of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-365)
Essai Clinique (Merck & Co.)   18 janvier 2024
Gastrointestinal metastases in renal cell carcinoma: A retrospective multicenter GETUG (Groupe d'Étude des Tumeurs Uro-Génitales) study.
European journal of cancer (Oxford, England : 1990)   15 janvier 2024
Perioperative dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin in muscle-invasive bladder cancer (VESPER): survival endpoints at 5 years in an open-label, randomised, phase 3 study.
The Lancet. Oncology   21 décembre 2023
PEACE1: A Prospective Randomised Phase III Study Of Androgen Deprivation Therapy With Or Without Docetaxel With Or Without Local Radiotherapy With Or Without Abiraterone Acetate And Prednisone In Patients With Metastatic Hormone-Naïve Prostate Cancer
Essai Clinique (Ipsen)   07 novembre 2023
Pembrolizumab and Enzalutamide in Patients with Abiraterone Acetate-Pretreated Metastatic Castration-Resistant Prostate Cancer: Cohort C of the Phase 1b/2 KEYNOTE-365 Study.
European urology oncology   06 novembre 2023
Données de survie à 5 ans de l’essai Getug-Afu Vesper évaluant dose-dense Methotrexate, Vinblastine, Doxorubicin, Cisplatin (DD-MVAC) versus Gemcitabine Cisplatin (gc) comme chimiothérapie périopératoire dans le cancer infiltrant de vessie
117e congrès français d'urologie   01 novembre 2023